Herberman, R. B., Nunn, M. E., Lavrin, D. H. & Asofsky, R. Effect of antibody to theta antigen on cell-mediated immunity induced in syngeneic mice by murine sarcoma virus. J. Natl Cancer Inst. 51, 1509–1512 (1973).
Google Scholar
Oldham, R. K. & Herberman, R. B. Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-iododeoxyuridine labeled target cells. J. Immunol. 111, 862–871 (1973).
Google Scholar
Takasugi, M., Mickey, M. R. & Terasaki, P. I. Reactivity of lymphocytes from normal persons on cultured tumor cells. Cancer Res. 33, 2898–2902 (1973).
Google Scholar
Kiessling, R., Klein, E. & Wigzell, H. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5, 112–117 (1975).
Google Scholar
Kiessling, R., Klein, E., Pross, H. & Wigzell, H. “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur. J. Immunol. 5, 117–121 (1975).
Google Scholar
Vivier, E. et al. Innate or adaptive immunity? The example of natural killer cells. Science 331, 44–49 (2011).
Google Scholar
Spits, H. et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145–149 (2013).
Google Scholar
Vivier, E. et al. Innate lymphoid cells: 10 years on. Cell 174, 1054–1066 (2018).
Google Scholar
Sojka, D. K. et al. Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. eLife 3, e01659 (2014).
Google Scholar
Moretta, L. et al. Human natural killer cells: their origin, receptors and function. Eur. J. Immunol. 32, 1205–1211 (2002).
Google Scholar
Moretta, A., Bottino, C., Mingari, M. C., Biassoni, R. & Moretta, L. What is a natural killer cell? Nat. Immunol. 3, 6–8 (2002).
Google Scholar
Vivier, E., Tomasello, E., Baratin, M., Walzer, T. & Ugolini, S. Functions of natural killer cells. Nat. Immunol. 9, 503–510 (2008).
Google Scholar
Morvan, M. G. & Lanier, L. L. NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer 16, 7–19 (2016).
Google Scholar
Freud, A. G., Mundy-Bosse, B. L., Yu, J. & Caligiuri, M. A. The broad spectrum of human natural killer cell diversity. Immunity 47, 820–833 (2017).
Google Scholar
Sender, R. et al. The total mass, number, and distribution of immune cells in the human body. Proc. Natl Acad. Sci. USA 120, e2308511120 (2023).
Google Scholar
Lanier, L. L., Le, A. M., Civin, C. I., Loken, M. R. & Phillips, J. H. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136, 4480–4486 (1986).
Google Scholar
Crinier, A. et al. High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice. Immunity 49, 971–986 (2018).
Google Scholar
Vivier, E. et al. High-dimensional single-cell analysis of natural killer cell heterogeneity in human blood. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-3870228/v1 (2024).
Hendricks, D. W. et al. Cutting edge: NKG2ChiCD57+ NK cells respond specifically to acute infection with cytomegalovirus and not Epstein-Barr virus. J. Immunol. 192, 4492–4496 (2014).
Google Scholar
Lopez-Verges, S. et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116, 3865–3874 (2010).
Google Scholar
Lopez-Verges, S. et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl Acad. Sci. USA 108, 14725–14732 (2011).
Google Scholar
Sun, J. C., Beilke, J. N. & Lanier, L. L. Adaptive immune features of natural killer cells. Nature 457, 557–561 (2009). This study, along with ref. 23, describes NK cells with memory-like functions.
Google Scholar
Cooper, M. A. et al. Cytokine-induced memory-like natural killer cells. Proc. Natl Acad. Sci. USA 106, 1915–1919 (2009).
Google Scholar
Cooper, M. A. & Yokoyama, W. M. Memory-like responses of natural killer cells. Immunol. Rev. 235, 297–305 (2010).
Google Scholar
Lee, J. et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 42, 431–442 (2015).
Google Scholar
Schlums, H. et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42, 443–456 (2015).
Google Scholar
Rückert, T., Lareau, C. A., Mashreghi, M. F., Ludwig, L. S. & Romagnani, C. Clonal expansion and epigenetic inheritance of long-lasting NK cell memory. Nat. Immunol. 23, 1551–1563 (2022).
Google Scholar
Brownlie, D. et al. Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood. Proc. Natl Acad. Sci. USA 118, e2016580118 (2021).
Google Scholar
Tang, F. et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 186, 4235–4251 (2023).
Google Scholar
Spits, H., Bernink, J. H. & Lanier, L. NK cells and type 1 innate lymphoid cells: partners in host defense. Nat. Immunol. 17, 758–764 (2016).
Google Scholar
Cortez, V. S. et al. SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-β signaling. Nat. Immunol. 18, 995–1003 (2017). This study, along with ref. 32, describes the TGFβ-induced transition of NK cells into ILC1-like cells with a decrease antitumour functions.
Google Scholar
Gao, Y. et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat. Immunol. 18, 1004–1015 (2017).
Google Scholar
Kansler, E. R. et al. Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies. Nat. Immunol. 23, 904–915 (2022).
Google Scholar
Scarno, G. et al. Divergent roles for STAT4 in shaping differentiation of cytotoxic ILC1 and NK cells during gut inflammation. Proc. Natl Acad. Sci. USA 120, e2306761120 (2023).
Google Scholar
Lopes, N. et al. Tissue-specific transcriptional profiles and heterogeneity of natural killer cells and group 1 innate lymphoid cells. Cell Rep. Med. 3, 100812 (2022).
Google Scholar
Nagasawa, M. et al. KLRG1 and NKp46 discriminate subpopulations of human CD117+CRTH2− ILCs biased toward ILC2 or ILC3. J. Exp. Med. 216, 1762–1776 (2019).
Google Scholar
Crinier, A. et al. Multidimensional molecular controls defining NK/ILC1 identity in cancers. Semin. Immunol. 52, 101424 (2021).
Google Scholar
Yudanin, N. A. et al. Spatial and temporal mapping of human innate lymphoid cells reveals elements of tissue specificity. Immunity 50, 505–519 (2019).
Google Scholar
Björkström, N. K., Strunz, B. & Ljunggren, H. G. Natural killer cells in antiviral immunity. Nat. Rev. Immunol. 22, 112–123 (2022).
Google Scholar
Vivier, E., Nunes, J. A. & Vely, F. Natural killer cell signaling pathways. Science 306, 1517–1519 (2004).
Google Scholar
Long, E. O. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol. Rev. 224, 70–84 (2008).
Google Scholar
Gasser, S., Orsulic, S., Brown, E. J. & Raulet, D. H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186–1190 (2005). This study, along with refs. 43–46, describes stress-induced ligands recognized by NK-cell-activating receptors.
Google Scholar
Raulet, D. H. & Guerra, N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 9, 568–580 (2009).
Google Scholar
Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727–729 (1999).
Google Scholar
Sen Santara, S. et al. The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature 616, 348–356 (2023).
Google Scholar
Brandt, C. S. et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495–1503 (2009).
Google Scholar
Wolf, N. K., Kissiov, D. U. & Raulet, D. H. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat. Rev. Immunol. 23, 90–105 (2023).
Google Scholar
Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9, 495–502 (2008).
Google Scholar
Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85–100 (2021).
Google Scholar
Laskowski, T. J., Biederstadt, A. & Rezvani, K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat. Rev. Cancer 22, 557–575 (2022).
Google Scholar
Hatjiharissi, E. et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism. Blood 110, 2561–2564 (2007).
Google Scholar
Friedman, D. et al. Natural killer cell immune synapse formation and cytotoxicity are controlled by tension of the target interface. J. Cell Sci. 134, jcs258570 (2021).
Google Scholar
Lettau, M., Paulsen, M., Schmidt, H. & Janssen, O. Insights into the molecular regulation of FasL (CD178) biology. Eur. J. Cell Biol. 90, 456–466 (2011).
Google Scholar
Braumuller, H. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361–365 (2013).
Google Scholar
Sharma, P. et al. Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652–1669 (2023).
Google Scholar
Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707–715 (2023).
Google Scholar
Demaria, O. et al. Harnessing innate immunity in cancer therapy. Nature 574, 45–56 (2019).
Google Scholar
Cao, L. L. & Kagan, J. C. Targeting innate immune pathways for cancer immunotherapy. Immunity 56, 2206–2217 (2023).
Google Scholar
Lopez-Soto, A., Gonzalez, S., Smyth, M. J. & Galluzzi, L. Control of metastasis by NK cells. Cancer Cell 32, 135–154 (2017). This report, along with refs. 60 and 61, describes anti-metastatic functions of NK cells.
Google Scholar
Liu, X. et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell 41, 272–287 (2023).
Google Scholar
Correia, A. L. et al. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature 594, 566–571 (2021).
Google Scholar
Bottcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022–1037 (2018). This study, along with ref. 63, describes the role of cytokines and chemokines secreted by NK cells in eliciting a multicellular antitumour immune response.
Google Scholar
Barry, K. C. et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat. Med. 24, 1178–1191 (2018).
Google Scholar
Kirchhammer, N. et al. NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity. Sci. Transl. Med. 14, eabm9043 (2022).
Google Scholar
Olson, J. A. et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 115, 4293–4301 (2010).
Google Scholar
Simonetta, F., Alvarez, M. & Negrin, R. S. Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation. Front. Immunol. 8, 465 (2017).
Google Scholar
Dhatchinamoorthy, K., Colbert, J. D. & Rock, K. L. Cancer immune evasion through loss of MHC class I antigen presentation. Front. Immunol. 12, 636568 (2021).
Google Scholar
Kärre, K., Ljunggren, H. G., Piontek, G. & Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675–678 (1986).
Google Scholar
Moretta, A. et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol. Rev. 155, 105–117 (1997).
Google Scholar
Yokoyama, W. M. Natural killer cell immune responses. Immunol. Res. 32, 317–325 (2005).
Google Scholar
Parham, P. MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 5, 201–214 (2005).
Google Scholar
André, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731–1743 (2018). This study, along with ref. 74, describes the role of monalizumab in promoting antitumour immunity.
Google Scholar
van Montfoort, N. et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell 175, 1744–1755 (2018).
Google Scholar
Andreae, S., Buisson, S. & Triebel, F. MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). Blood 102, 2130–2137 (2003).
Google Scholar
Baixeras, E. et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J. Exp. Med. 176, 327–337 (1992).
Google Scholar
Kisielow, M., Kisielow, J., Capoferri-Sollami, G. & Karjalainen, K. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur. J. Immunol. 35, 2081–2088 (2005).
Google Scholar
Merino, A. et al. Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. J. Clin. Invest. 129, 3770–3785 (2019).
Google Scholar
Huard, B. et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc. Natl Acad. Sci. USA 94, 5744–5749 (1997).
Google Scholar
Workman, C. J., Rice, D. S., Dugger, K. J., Kurschner, C. & Vignali, D. A. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur. J. Immunol. 32, 2255–2263 (2002).
Google Scholar
Hu, S., Liu, X., Li, T., Li, Z. & Hu, F. LAG3 (CD223) and autoimmunity: emerging evidence. J. Autoimmun. 112, 102504 (2020).
Google Scholar
Kouo, T. et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol. Res. 3, 412–423 (2015).
Google Scholar
Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520–531 (2018).
Google Scholar
Sordo-Bahamonde, C. et al. LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia. Cancers 13, 2112 (2021).
Google Scholar
Wang, J. et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell 176, 334–347 (2019).
Google Scholar
Khan, M., Arooj, S. & Wang, H. NK cell-based immune checkpoint inhibition. Front. Immunol. 11, 167 (2020).
Google Scholar
Ndhlovu, L. C. et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119, 3734–3743 (2012).
Google Scholar
Seo, H. et al. IL21 therapy combined with PD-1 and Tim-3 blockade provides enhanced NK cell antitumor activity against MHC class I-deficient tumors. Cancer Immunol. Res. 6, 685–695 (2018).
Google Scholar
da Silva, I. P. et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol. Res. 2, 410–422 (2014).
Google Scholar
Xu, L. et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int. Immunopharmacol. 29, 635–641 (2015).
Google Scholar
Jiang, W. et al. Tim-3 blockade elicits potent anti-multiple myeloma immunity of natural killer cells. Front. Oncol .12, 739976 (2022).
Google Scholar
Sanchez-Correa, B. et al. DNAM-1 and the TIGIT/PVRIG/TACTILE axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers 11, 877 (2019).
Google Scholar
Alteber, Z. et al. Therapeutic targeting of checkpoint receptors within the DNAM1 axis. Cancer Discov. 11, 1040–1051 (2021).
Google Scholar
Zhang, Q. et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat. Immunol. 19, 723–732 (2018).
Google Scholar
Temming, A. R. et al. Functional attributes of antibodies, effector cells, and target cells affecting nk cell-mediated antibody-dependent cellular cytotoxicity. J. Immunol. 203, 3126–3135 (2019).
Google Scholar
van der Horst, H. J., Nijhof, I. S., Mutis, T. & Chamuleau, M. E. D. Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies. Cancers 12, 3041 (2020).
Google Scholar
Shields, R. L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733–26740 (2002).
Google Scholar
Suzuki, E. et al. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin. Cancer Res. 13, 1875–1882 (2007).
Google Scholar
Wang, X., Mathieu, M. & Brezski, R. J. IgG Fc engineering to modulate antibody effector functions. Protein Cell 9, 63–73 (2018).
Google Scholar
Rothe, A. et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 125, 4024–4031 (2015).
Google Scholar
Wiernik, A. et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 × 33 bispecific killer cell engager and ADAM17 inhibition. Clin. Cancer Res. 19, 3844–3855 (2013).
Google Scholar
Vallera, D. A. et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother. Radiopharm. 28, 274–282 (2013).
Google Scholar
Gleason, M. K. et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol. Cancer Ther. 11, 2674–2684 (2012).
Google Scholar
Gleason, M. K. et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123, 3016–3026 (2014).
Google Scholar
Vallera, D. A. et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin. Cancer Res. 22, 3440–3450 (2016).
Google Scholar
Schmohl, J. U. et al. Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity. Cancer Res. Treat. 49, 1140–1152 (2017).
Google Scholar
Felices, M. et al. Potent cytolytic activity and specific IL15 delivery in a second-generation trispecific killer engager. Cancer Immunol. Res. 8, 1139–1149 (2020).
Google Scholar
Miller, J. et al. P618: second-generation CD19 targeting tri-specific killer engager drives robust nk cell function against B cell malignancies. HemaSphere 6, 517–518 (2022).
Google Scholar
Romee, R. et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 121, 3599–3608 (2013).
Google Scholar
Coudert, J. D., Scarpellino, L., Gros, F., Vivier, E. & Held, W. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood 111, 3571–3578 (2008).
Google Scholar
Chan, W. K. et al. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma. Cancer Immunol. Res. 6, 776–787 (2018).
Google Scholar
Raynaud, A. et al. Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response. Oncoimmunology 10, 1854529 (2020).
Google Scholar
Safran, H. et al. Phase 1/2 study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: phase 1 DF1001 monotherapy dose-escalation results. J. Clin. Oncol. 41, 2508–2508 (2023).
Google Scholar
von Strandmann, E. P. et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107, 1955–1962 (2006).
Google Scholar
Wang, Y. et al. BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma. J. Immunother. 43, 175–188 (2020).
Google Scholar
Gauthier, L. et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell 177, 1701–1713 (2019).
Google Scholar
Pessino, A. et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J. Exp. Med. 188, 953–960 (1998).
Google Scholar
Walzer, T. et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc. Natl Acad. Sci. USA 104, 3384–3389 (2007).
Google Scholar
Gauthier, L. et al. Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123. Nat. Biotechnol. 41, 1296–1306 (2023).
Google Scholar
Colomar-Carando, N. et al. Exploiting natural killer cell engagers to control pediatric B-cell precursor acute lymphoblastic leukemia. Cancer Immunol. Res. 10, 291–302 (2022).
Google Scholar
Demaria, O. et al. Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. Cell Rep. Med. 3, 100783 (2022). This study describes the first tetraspecific NK cell engagers armed with a variant of IL-2.
Google Scholar
Arulanandam, A. et al. 756P glypican-3 (GPC3) and NKp46 directed FLEX-NK engager antibody (CYT-303) recruits natural killer (NK) cells to tumors in a preclinical hepatocellular carcinoma (HCC) mouse model. Ann. Oncol. 33, S889 (2022).
Google Scholar
Lin, L. et al. P842: novel multifunctional tetravalent CD38 NKp46 FLEX-NK engagers actively target and kill multiple myeloma cells. HemaSphere 6, 736–737 (2022).
Google Scholar
Pende, D. et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190, 1505–1516 (1999).
Google Scholar
Pinheiro, P. F., Justino, G. C. & Marques, M. M. NKp30—a prospective target for new cancer immunotherapy strategies. Br. J. Pharmacol. 177, 4563–4580 (2020).
Google Scholar
Medjouel Khlifi, H., Guia, S., Vivier, E. & Narni-Mancinelli, E. Role of the ITAM-bearing receptors expressed by natural killer cells in cancer. Front. Immunol. 13, 898745 (2022).
Google Scholar
Pesce, S. et al. B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology 4, e1001224 (2015).
Google Scholar
Berrien-Elliott, M. M., Jacobs, M. T. & Fehniger, T. A. Allogeneic natural killer cell therapy. Blood 141, 856–868 (2023).
Google Scholar
Piccinelli, S., Romee, R. & Shapiro, R. M. The natural killer cell immunotherapy platform: an overview of the landscape of clinical trials in liquid and solid tumors. Semin. Hematol. 60, 42–51 (2023).
Google Scholar
Nahi, H. et al. Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. Cell Rep. Med. 3, 100508 (2022).
Google Scholar
Li, L. et al. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci. Adv. 9, eadd6997 (2023).
Google Scholar
Foltz, J. A., Moseman, J. E., Thakkar, A., Chakravarti, N. & Lee, D. A. TGFβ imprinting during activation promotes natural killer cell cytokine hypersecretion. Cancers 10, 423 (2018).
Google Scholar
Terrén, I. et al. Cytokine-induced memory-like NK cells: from the basics to clinical applications. Front. Immunol. 13, 884648 (2022).
Google Scholar
Fehniger, T. A. & Cooper, M. A. Harnessing NK cell memory for cancer immunotherapy. Trends Immunol. 37, 877–888 (2016).
Google Scholar
Kerbauy, L. N. et al. Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies. Clin. Cancer Res. 27, 3744–3756 (2021). This study describes the advantages of combining NK cell infusions and NK cell engagers.
Google Scholar
Shapiro, R. M. et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J. Clin. Invest. 132, e154334 (2022).
Google Scholar
Oyer, J. L. et al. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment. Cytotherapy 18, 653–663 (2016).
Google Scholar
Denman, C. J. et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7, e30264 (2012).
Google Scholar
Oyer, J. L. et al. Cryopreserved PM21-particle-expanded natural killer cells maintain cytotoxicity and effector functions in vitro and in vivo. Front. Immunol. 13, 861681 (2022).
Google Scholar
Coyle, K. M., Hawke, L. G. & Ormiston, M. L. Addressing natural killer cell dysfunction and plasticity in cell-based cancer therapeutics. Cancers 15, 1743 (2023).
Google Scholar
Balzasch, B. M. & Cerwenka, A. Microenvironmental signals shaping NK-cell reactivity in cancer. Eur. J. Immunol. 53, e2250103 (2023).
Google Scholar
Tong, L. et al. NK cells and solid tumors: therapeutic potential and persisting obstacles. Mol. Cancer 21, 206 (2022).
Google Scholar
Burga, R. A. et al. Engineering the TGFβ receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma. Clin. Cancer Res. 25, 4400–4412 (2019).
Google Scholar
Solocinski, K. et al. Overcoming hypoxia-induced functional suppression of NK cells. J. Immunother. Cancer 8, e000246 (2020).
Google Scholar
Zhu, H. et al. Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes in vivo persistence and enhances anti-tumor activity. Cell Stem Cell 27, 224–237 (2020).
Google Scholar
Daher, M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137, 624–636 (2021).
Google Scholar
Loftus, R. M. et al. Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice. Nat. Commun. 9, 2341 (2018).
Google Scholar
Guedan, S., Calderon, H., Posey, A. D. Jr & Maus, M. V. Engineering and design of chimeric antigen receptors. Mol. Ther. Methods Clin. Dev. 12, 145–156 (2019).
Google Scholar
Biederstädt, A. & Rezvani, K. Engineering the next generation of CAR-NK immunotherapies. Int. J. Hematol. 114, 554–571 (2021).
Google Scholar
Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020). This study describes the clinical efficacy of CAR NK cells against B cell malignancies.
Google Scholar
Leem, G. et al. Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: a multicenter open-label phase 1/2a trial. Cancers 14, 4229 (2022).
Google Scholar
Marotel, M., Hasim, M. S., Hagerman, A. & Ardolino, M. The two-faces of NK cells in oncolytic virotherapy. Cytokine Growth Factor Rev. 56, 59–68 (2020).
Google Scholar
Ruscetti, M. et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362, 1416–1422 (2018).
Google Scholar
Pan, R., Ryan, J., Pan, D., Wucherpfennig, K. W. & Letai, A. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell 185, 1521–1538 (2022).
Google Scholar
Walle, T. et al. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci. Adv. 8, eabh4050 (2022).
Google Scholar
Delconte, R. B. et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat. Immunol. 17, 816–824 (2016).
Google Scholar
Cichocki, F. et al. Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. Nat. Commun. 13, 7341 (2022).
Google Scholar
Cichocki, F. et al. Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma. Sci. Transl. Med. 15, eade3341 (2023).
Google Scholar
Lordo, M. R., Stiff, A. R., Oakes, C. C. & Mundy-Bosse, B. L. Effects of epigenetic therapy on natural killer cell function and development in hematologic malignancy. J. Leukocyte Biol. 113, 518–524 (2023).
Google Scholar
Young, R. M., Engel, N. W., Uslu, U., Wellhausen, N. & June, C. H. Next-generation CAR T-cell therapies. Cancer Discov. 12, 1625–1633 (2022).
Google Scholar
Reighard, S. D. et al. Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells. Cell Rep. Med. 1, 100003 (2020).
Google Scholar